Suggested remit: To appraise the clinical and cost effectiveness of avacopan within its marketing authorisation for treating anti-neutrophil cytoplasmic antibody-associated vasculitis.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA 2018
ID number 1581

Provisional Schedule

Committee meeting: 2 07 July 2022
Expected publication 07 September 2022

Project Team

Project lead Kate Moore

Email enquiries

Stakeholders

Companies sponsors Vifor Pharma UK (avacopan)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Vasculitis UK
Professional groups British Association for Paediatric Nephrology
  British Association of Dermatologists
  British Society for Rheumatology
  Royal College of Physicians
  UK Kidney Association
  UK Renal Pharmacy Group
Comparator companies Novartis (mycophenolate)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups UK and Ireland Vasculitis Rare Disease Group

Timeline

Key events during the development of the guidance:

Date Update
24 May 2022 - 17 June 2022 Draft guidance
05 May 2022 Committee meeting
25 August 2021 Invitation to participate
19 February 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of avacopan for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during late-August 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
19 February 2021 In progress. Topic is in progress
23 September 2020 - 21 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual